Please login or register first to view this content.
Cardiovascular Disease Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
Companies Selling Supplements With Claims to Treat CVD Get Hit With Warning Letters
Benefits of Dapagliflozin in Heart Failure Similar for Men, Women
How Does Risk for CV Events Differ Between Tofacitinib and TNFi in RA?
American Medical Association Pushes for Permanent Use of Standard Time
Weak Association Observed Between Systemic Vasculitis and Myocardial Infarction
Myocarditis Up After Second Dose of mRNA-1273 Versus BNT162b2
Baxdrostat Studied in Treatment-Resistant Hypertension
Low-Dose Statin Bests Six Commonly Used Cholesterol Health Supplements
Furosemide vs Torsemide: Similar Outcomes Observed in Heart Failure Study
Empagliflozin Cuts Risk of Kidney Disease Progression, CV Death in CKD Patients
October 2022: Notable Drug Approvals
October 2022 Recap: Drug Pipeline Updates
Meta-Analysis Shows Decrease in Dementia Risk With HTN Treatment
GI Bleeding Lower With Apixaban vs Other DOACs in A-Fib
Benefit of Ticagrelor-Aspirin in Stroke Patients Tied to Renal Function
Patients With IBD at Increased Risk for CVD, Renal Complications After COVID-19
Quinapril-Hydrochlorothiazide Tablets Recalled Due to Nitrosamine Impurity
Tadliq, an Oral Suspension Formulation of Tadalafil, Now Available
